Kirsner R S, Federman D
University of Miami School of Medicine, Florida, USA.
Am Fam Physician. 1995 Jul;52(1):237-40, 243-4.
Psoriasis, a common skin disorder, affects over 1 percent of the population of the United States. The majority of these patients have limited disease that can be managed with topical therapy. Topical treatment includes corticosteroids, tar, anthralin and keratolytic agents. Calcipotriene, a new topical treatment for psoriasis of mild to moderate severity, is a vitamin D derivative that inhibits epidermal cell proliferation in vitro. Treatment with calcipotriene results in decreased redness, scaling and thickness of the plaque. Calcipotriene is comparable to mid-potency topical corticosteroids in efficacy, but it does not cause skin atrophy and apparently does not lead to tachyphylaxis. Irritant dermatitis is a common side effect of calcipotriene, especially when it is applied to the face. Careful patient monitoring is recommended because alterations in calcium metabolism have been reported to occur with use of calcipotriene.
银屑病是一种常见的皮肤病，在美国超过1%的人口受其影响。这些患者中的大多数病情有限，可用局部治疗。局部治疗包括皮质类固醇、焦油、蒽林和角质溶解剂。卡泊三醇是一种治疗轻至中度银屑病的新型局部用药，它是一种维生素D衍生物，在体外可抑制表皮细胞增殖。使用卡泊三醇治疗可使斑块的发红、脱屑和厚度减轻。卡泊三醇在疗效上与中效局部皮质类固醇相当，但不会引起皮肤萎缩，且显然不会导致快速耐受。刺激性皮炎是卡泊三醇常见的副作用，尤其是用于面部时。建议对患者进行仔细监测，因为据报道使用卡泊三醇会导致钙代谢改变。
